About: acn

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1.     Sustainable & Climate TechnologyAlbacastor Technology Limited2.     AIGreen Limited 3.     Asgard Group Limited 4.     Formwork IO5.     Green Vigor Limited6.     Laputa Eco-Construction Material Company Limited7.     LeafIoT Technology Limited8.     Plasticvore Chain Ltd 9.     AI and Software Solutions Cogniser Infotech Ltd10.  D-Engraver Limited11.  Midas Analytics Limited 12.  OxGen Holdings Limited13.  Pantheon Lab Limited14.  SagaDigits Limited15.  Robotics and Microelectronics TechnologyAnlaseo Technology Limited16.  Bacbudy Limited17.  Cybercrystal Technology Co., Limited18.  Harmony SkyTech Limited19.  Oriental Materials Hong Kong Limited20.  Robocore Technology Limited21.  Health TechnologyEieling Technology Limited22.  Hong Kong Bionic Beet Robotics Limited23.  Point Fit Technology Limited 24.  UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion.  During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IRVINE, CA, June 7, 2026 - (ACN Newswire via SeaPRwire.com) - iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings a range of promotional offers and localized services to customers in Hong Kong and Southeast Asia, reflecting the company’s ongoing commitment to enhancing accessibility and customer experience across international markets.Founded in 1996, iHerb has expanded its operations to 185 countries and regions and now serves more than 11 million active users worldwide. Through its direct sourcing model and global fulfillment network, the company has focused on providing consumers with access to a broad range of international health, wellness, beauty, and personal care products.Unlike traditional cross-border retail models that often involve multiple intermediaries, iHerb purchases products directly from manufacturers and distributes them through its own warehouse network. The company stated that this approach helps improve supply chain transparency and product traceability while streamlining international delivery.As part of the 618 campaign, iHerb highlighted a selection of products from popular categories frequently purchased by consumers, including dietary supplements, personal care products, sports nutrition items, and beauty products.Among the featured products are:California Gold Nutrition LactoBif(R) 30 Billion Probiotics (CGN00965), a probiotic supplement packaged in individually sealed blister packs for convenient storage and transportation.Doctor's Best High Absorption Magnesium (DRB00087), a magnesium supplement formulated using Albion(R) TRAACS(R) chelation technology.Nature's Way Alive! Hair, Skin and Nails Gummies (NWY11534), a strawberry-flavored gummy supplement containing vitamins, collagen, and other nutritional ingredients.Metagenics OmegaGenics(R) Fish Oil EPA-DHA (MTG93873), a fish oil supplement containing EPA, DHA, and omega-3 fatty acids.ProHealth Longevity NMN Pro 1000 (PHV77904), an NMN supplement designed for adult consumers interested in wellness-focused nutritional products.The company noted that these products represent some of the diverse categories available on the platform, which currently offers nearly 3,000 brands and more than 50,000 products globally.To commemorate its 29th anniversary and the 618 Shopping Festival, iHerb announced several promotional initiatives for customers in Hong Kong and Southeast Asia:New customers can use the code WELCOME7 to receive a first-order discount.From June 11 to June 20, customers can use 618SALE26 for sitewide promotional savings.Additional regional promotions are available through the end of June using code 6HK75, subject to applicable terms and conditions.Customers in Hong Kong may qualify for free shipping on eligible orders and access local express delivery options.In addition to promotional activities, iHerb continues to expand localized services across Asian markets. Customers can shop through the company's website and mobile application, with support for local currencies and multiple payment methods, including credit cards and digital wallets.As iHerb marks its 29th anniversary, the company stated that it will continue investing in supply chain infrastructure, customer service, and regional fulfillment capabilities to support consumers seeking access to international health and wellness products.Company: iHerb, LLCContact Person: Kelly ChaiEmail: china.sm@iherb.com Website: iherb.com Telephone: (1) 951 6163600 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

塔什干，烏茲別克斯坦，2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 由香港特別行政區行政長官李家超率領、香港貿易發展局（香港貿發局）組織的商貿代表團，於6月1至3日完成以哈薩克斯坦為首站的訪問後，於6月4至5日訪問中亞之行最後一站烏茲別克斯坦首都塔什干，與當地政府及企業的高層要員會面，成功推動多領域的合作機遇。香港貿發局將全力跟進訪問期間促成的重點項目，為企業提供專業的後續商貿配對及支援服務，推動項目早日落地的同時，亦將繼續協助香港企業發掘更多國際合作機遇。單計貿發局組織的商貿代表團於訪問哈薩克斯坦及烏茲別克斯坦期間，已促成66份備忘錄及合作協議，涵蓋經貿、投資、金融、科技、航空等領域。此外，在政府層面簽訂另外15份合作文件，而非代表團成員就學術、文化等範疇亦簽署15份備忘錄，即今次訪問共達成96份備忘錄及合作協議，為香港、內地、哈薩克斯坦及烏茲別克斯坦深化經貿往來奠定良好基礎，凸顯香港作為內地企業出海的重要平台角色，並進一步推動與中亞市場的長遠合作，各方亦期望未來有更多中亞企業訪港，參與包括「一帶一路高峰論壇」、「香港國際創科展」等貿發局旗艦國際會議及展覽，把握香港作為國際商貿樞紐所帶來的機遇，深化合作。代表團在烏茲別克斯坦期間，與當地政府高層、工商機構及企業代表會面，包括烏茲別克斯坦投資、工業與貿易部、烏茲別克斯坦工商會及烏茲別克斯坦IT科技園等，深入了解當地經濟發展、市場環境及投資機遇。行政長官李家超總結中亞之行時表示：「這次訪問有三個目的：第一是進一步開拓新興市場，為推動長遠經貿發展奠定基礎。第二是加強政府與政府之間的關係往來，推進雙方更緊密合作。第三是構建樞紐對樞紐的合作模式。這次我率領75位來自香港和內地企業的商貿代表及專業人員，訪問中亞五國中兩個大國--哈薩克斯坦和烏茲別克斯坦，出席超過20場活動，考察了多個金融、創科、基建項目。訪問是成功的，有八大成果。」例如他提到，他分別與兩國的總統、總理和多位高層官員會面，雙方同意加強高層溝通聯繫及多方面協作。烏茲別克斯坦政府已同意在香港設立總領事館。此外，雙方簽訂多項協議，包括涉實質金額的項目。大家認同樞紐對樞紐的合作方向可帶來兩個區域更廣更闊的合作空間和高質量發展，雙方會增加高層互訪並支持對方的活動，共同擴大網絡。為深化經貿合作，香港特區政府與香港貿發局在烏茲別克斯坦合辦商務晚宴，吸引約230名商界領袖及主要官員出席。香港貿發局主席馬時亨教授指出：「今次中亞之行成果豐碩，再次確認了中亞國家對香港『橋樑』角色的信任。在開拓哈薩克斯坦及烏茲別克斯坦等新興市場過程中，香港憑藉國際信譽、健全制度、世界級專業服務及貿發局全球網絡平台，既是內地企業『走出去』的重要支點，亦是海外企業進入內地市場的橋頭堡，有效促進雙向投資及貿易往來。這種『引進來、走出去』的雙向流動，充分展現香港在『一帶一路』中不可替代的價值，以及貿發局作為企業雙向拓展首選平台的優勢。」是次代表團由來自香港及內地的商界領袖組成，內地企業代表來自17個省市，涵蓋金融及專業服務、物流運輸、創新科技、貿易、綠色產業以至傳媒等多個界別。本次外訪亦首次邀請新聞行業協會代表隨團，以呼應《施政報告》提出協助本地傳媒發展海外網絡、說好「香港故事」。代表團在哈薩克斯坦期間共促成43份備忘錄（MoU）及合作協議（Agreement）：1香港貿易發展局與哈薩克國家企業家協會（阿塔梅肯）2香港貿易發展局與阿斯塔納國際金融中心3香港貿易發展局與哈薩克國立科技大學4香港機場管理局與阿拉木圖國際機場5一帶一路總商會與哈薩克國家企業家協會（阿塔梅肯）6一帶一路總商會與大宗港聯數字交易股份有限公司與Eurasian Trading System Export” International Commodity Exchange (ETSE)7一帶一路總商會與 JINGSH CONSULTING LLP8香港中華廠商聯合會與哈薩克國家企業家協會（阿塔梅肯）9數碼港與阿斯塔納國際科技園10香港工業總會與哈薩克斯坦人工智能與數字發展部11香港交易及結算所有限公司與Astana International Exchange (AIX)12香港交易及結算所有限公司與阿斯塔納國際金融中心13香港科技園公司與阿斯塔納國際科技園14港深創新及科技園有限公司與阿斯塔納國際科技園15香港總商會與哈薩克國家企業家協會（阿塔梅肯）16香港律師會與哈薩克斯坦國家律師協會17中國銀行(香港)有限公司與哈薩克中國銀行與拜特雷克國家投資控股公司18中國銀行(香港)有限公司與薩姆魯克-卡澤納投資公司19博時基金（國際）有限公司與哈薩克人民儲蓄銀行20國泰航空與阿拉木圖國際機場與阿拉木圖政府（旅遊發展部）21中國國際金融股份有限公司與自由控股公司22中國國際金融股份有限公司與薩姆魯克-卡澤納投資公司23中國國際金融股份有限公司與阿斯塔納國際金融中心24中國國際金融股份有限公司與阿斯塔納航空25德勤中國與寰泰能源股份有限公司26易達資本與Dasco Capital Ltd.27易達資本與阿斯塔納國際金融中心28易達資本與江蘇關懷醫療科技（集團）有限公司與薩姆魯克-卡澤納投資公司29高鋒集團與Gas Energy Solution LLP30香港新聞行政人員協會與香港報業公會與Khabar Agency JSC31怡和控股有限公司與KIDF32佳鑫國際資源投資有限公司與哈薩克工業和建設部33科能三維技術（醫療）有限公司與哈薩克腫瘤放射研究所34電訊盈科有限公司與Kazakhtelecom35電訊盈科有限公司與Khabar Agency JSC36南華早報與阿斯塔納國際金融中心37南華早報與戈壁創投與阿斯塔納國際科技園與汗騰格裡創新中心38大豆天地農業科技有限公司與哈薩克斯坦國家糧食集團39渣打銀行與哈薩克斯坦開發銀行40渣打銀行與杭州熱聯集團股份有限公司41善水資本香港有限公司與自由控股公司42英文虎報與Freedom Horizons43沃森生物技術股份有限公司與Gold Astrum LLC代表團在烏茲別克斯坦期間共促成23份備忘錄（MoU）及合作協議（Agreement）：1香港貿易發展局與烏茲別克斯坦工商會2香港貿易發展局與烏茲別克斯坦IT科技園3香港機場管理局與Fly Khiva Group4一帶一路總商會與大宗港聯數字交易股份有限公司與中化塑料有限公司"MCHJ XK"5一帶一路總商會與烏茲別克斯坦工商會6一帶一路總商會與JINGSH CONSULTING LLP7香港中華廠商聯合會與烏茲別克斯坦工商會8香港工業總會與塔什干市政府9數碼港與烏茲別克斯坦IT科技園10香港總商會與烏茲別克斯坦工商會11香港律師會與烏茲別克斯坦共和國律師協會12甲級能源有限公司與烏茲別克斯坦扎拉夫尚黃金集團13中國國際金融股份有限公司與烏茲別克斯坦共和國對外經濟活動國家銀行14中國國際金融股份有限公司與烏茲別克斯坦共和國塔什干市政府15德勤中國與東方集團與中國國際金融股份有限公司16高鋒集團與Automated Solutions Center17善水資本香港有限公司與烏茲別克 - 阿曼投資公司18善水資本香港有限公司與CSCEC INTERNATIONAL MCHJXK（中國建築國際集團有限公司）19善水資本香港有限公司與烏茲別克斯坦共和國塔什干市政府20渣打銀行與烏茲別克斯坦共和國塔什干市政府21長春金賽藥業有限責任公司與Vita Group Farm22廣州醫藥集團有限公司與烏茲別克斯坦 ADN 醫藥工業股份公司23陝西天潤科技股份有限公司與烏茲別克斯坦共和國國家稅務委員會轄下地籍局遙感部其他非團員機構也藉此機會在教育、文化等多個領域達成合作：1甲級能源有限公司與哈薩克斯坦人工智能與數字發展部2甲級能源有限公司與自由控股公司3中國移動國際有限公司與哈郵圓通4香港城市大學與哈薩克斯坦科學與高等教育部下屬國際計劃中心5香港城市大學與薩特巴耶夫國立技術大學6香港城市大學與塔什干國立技術大學7香港教育大學與納扎爾巴耶夫大學8香港電訊與香港教育大學9香港理工大學與納扎爾巴耶夫大學10香港理工大學與El-Yurt Umidi基金會11香港理工大學與新烏茲別克斯坦大學12香港高等教育科技學院與BILIM-INNOVATION國際社會基金會13香港高等教育科技學院與L.N. Gumilyov歐亞國立大學14建銀國際與烏茲別克斯坦銀行業協會15西九文化區管理局 - 香港故宮文化博物館與烏茲別克斯坦國家歷史博物館圖片下載：https://bit.ly/4fmUpRL行政長官李家超總結中亞之行時表示：「這次訪問有三個目的：第一是進一步開拓新興市場，為推動長遠經貿發展奠定基礎。第二是加強政府與政府之間的關係往來，推進雙方更緊密合作。第三是構建樞紐對樞紐的合作模式。這次我率領75位來自香港和內地企業的商貿代表及專業人員，訪問中亞五國中兩個大國--哈薩克斯坦和烏茲別克斯坦，出席超過20場活動，考察了多個金融、創科、基建項目。訪問是成功的，有八大成果。」香港貿易發展局主席馬時亨教授聯同行政長官李家超、特區政府主要官員及代表團成員會見傳媒時表示，在行政長官率領下的中亞之行，成功為商界打開中亞市場合作的大門。香港特區政府與香港貿發局在烏茲別克斯坦合辦商務晚宴，吸引約230名商界領袖及主要官員出席。香港貿發局主席馬時亨教授於晚宴上表示：「今次中亞之行成果豐碩，再次確認了中亞國家對香港『橋樑』角色的信任。在開拓哈薩克斯坦及烏茲別克斯坦等新興市場過程中，香港憑藉國際信譽、健全制度、世界級專業服務及貿發局全球網絡平台，既是內地企業『走出去』的重要支點，亦是海外企業進入內地市場的橋頭堡，有效促進雙向投資及貿易往來。這種『引進來、走出去』的雙向流動，充分展現香港在『一帶一路』中不可替代的價值，以及貿發局作為企業雙向拓展首選平台的優勢。」代表團於烏茲別克斯坦期間促成23份備忘錄及合作協議。代表團與烏茲別克斯坦投資、工業與貿易部就兩地商貿發展以及投資機遇深入交流，期間香港貿發局主席馬時亨教授（右）與烏茲別克斯坦共和國副總理Khodjayev Jamshid Abdukhakimovich會面。代表團與烏茲別克斯坦工商會的多名代表會面，深入了解當地經濟發展、市場環境及投資機遇。代表團參觀烏茲別克斯坦IT科技園，了解當地創新科技發展。傳媒查詢新聞界如有查詢，請聯絡：香港貿易發展局傳訊及公共事務部：徐俊逸電話：(852) 2584 4395電郵：johnny.cy.tsui@hktdc.org張希汶電話：(852) 2584 4272電郵：serena.hm.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年！成立於1966年，香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業（尤其是中小企）開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong.  During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC  During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395  Email: johnny.cy.tsui@hktdc.orgSerena Cheung  Tel: (852) 2584 4272  Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 領先電子產品生產商華訊股份有限公司（「華訊」或「集團」）（股份代號：833）宣佈其位於馬來西亞檳城的生產基地正式啟用。該新設施為集團多元製造佈局策略的重要里程碑，標誌著拓展中國內地以外產能，並進一步強化東南亞的生產網絡。該檳城廠佔地約60,000平方呎，設有12條生產線，每月產能達250,000至300,000件。該廠作為原始設備製造（OEM）生產基地，主要生產銷往國際市場的工業電子產品、環境控制設備及電子電源模組。新增產能不僅擴大集團的整體製造規模，亦滿足持續增長的市場需求，為未來業務拓展提供穩固基礎。是次啟用乃承接集團於2025年完成的多項策略性部署，包括收購位於馬來西亞檳城及越南胡志明市的製造業務。進軍馬來西亞為集團首次在中國內地以外建立生產據點。集團於2025年8月完成收購檳城廠後，展開擴建及升級，引入先進設備及優化生產流程，以提升效率及品質管理水平。該設施現時生產灌溉感應器、恆溫器、保安設備及鋰電池組。華訊主席兼執行董事林賢奇先生表示：「檳城廠在推動集團建立更多元化製造網絡的策略中發揮關鍵作用。配合越南業務的拓展，我們正持續強化生產能力，提升整體供應鏈的靈活性，有助進一步增強集團的韌性與應變能力，使我們能在瞬息萬變的全球環境下更有效支援客戶業務發展。」華訊行政總裁兼執行董事林子泰先生補充指：「檳城廠正穩步提升產能，並已承接現有及新客戶的新增訂單。隨著生產線擴充及系統升級完成，產能將更趨充裕，以配合未來需求。集團亦正評估於馬來西亞設立另一個具相若產能的生產基地，推動下一階段的業務增長。」 馬來西亞官方代表、華訊董事局成員及管理層於當地新廠房舉行剪綵儀式。 華訊馬來西亞生產基地配備12條生產線，每月產能達250,000至300,000件，進一步擴大集團製造規模，滿足持續增長的客戶需求。有關華訊股份有限公司（股份代號：833）華訊股份有限公司主要從事設計及生產多款高質量且時尚的電子產品。本公司為明晟（「MSCI」）香港微型指數成份股。有關詳情，請瀏覽網頁http://www.alltronics.com.hk/。  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m².  Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 君聖泰醫藥（股票代碼：2511.HK），一家專注於心腎代謝系統疾病（CKM）、開發多功能多靶點療法的創新生物醫藥公司，今日在英國格拉斯哥舉行的第63屆歐洲腎臟協會（ERA）年會上，以口頭報告的形式公佈了其核心產品HTD1801的腎臟保護最新研究結果。HTD1801是全球首創的靶向AMPK-NLRP3通路的抗炎代謝調節劑（AIMM）。在已完成的III期臨床研究（SYMPHONY-1&2）中，HTD1801顯著改善了基線eGFR為60–90 mL/min/1.73m²的2型糖尿病（T2DM）患者的腎功能。治療52周後，這些患者的eGFR平均升高了+3.08 mL/min/1.73m²（95% CI: 0.46–5.70），且未出現高濾過或體液瀦留。這些結果提示，HTD1801和現有機制藥物有差異化優勢，並具有延緩甚至逆轉疾病進程的潛力。本項研究進一步解釋了上述臨床結果。該研究由君聖泰醫藥與中國醫學科學院醫藥生物技術研究所蔣建東院士研究團隊共同完成，結果顯示，在葡萄糖及棕櫚酸誘導的足細胞損傷模型中，HTD1801可顯著提升足細胞存活率、抑制細胞凋亡；恢復足細胞關鍵結構蛋白nephrin與podocin的表達；並顯著降低代謝性炎症通路中磷酸化NF-κB及凋亡執行蛋白caspase-3水平。在糖尿病腎病（DN）模型中，HTD1801可呈劑量依賴性改善腎臟組織結構，降低腎小管損傷評分，減輕腎臟炎症及纖維化病變，並顯著降低24小時尿微量白蛋白水平。該研究系統性闡明HTD1801可抑制足細胞炎症與凋亡、穩定腎小球結構，進一步揭示了HTD1801的腎臟保護潛力，為其成為慢性腎病（CKD）及其他腎臟疾病的潛在療法提供了重要的科學依據。摘要標題：HTD1801減輕足細胞凋亡與腎小球損傷--腎臟保護機理探析報告編號：2243報告時間：2026年6月4日，星期四，上午8:15（英國夏令時間）報告形式：口頭報告報告人：Filip Surmont博士，君聖泰醫藥首席醫學官君聖泰醫藥首席醫學官Filip Surmont博士表示："此次研究首次從足細胞與腎小球層面揭示了HTD1801的腎臟保護作用。臨床研究與臨床前研究結果的高度一致，進一步證實了HTD1801在CKD或其他腎臟疾病中直擊核心病理進程的能力，彰顯了其重要治療潛力。我們將持續推進HTD1801在CKD等適應症的臨床開發，力求為全球腎病患者帶來更多創新的治療選擇。"關於HTD1801HTD1801是一款全球首創的新分子實體，旨在解決心腎代謝系統疾病（CKM）的未滿足臨床需求。HTD1801作為單一分子，是具有獨特雙機制的口服抗炎及代謝調節劑（AIMM），通過激活AMPK及抑制NLRP3炎症小體發揮其生物學活性；這種互補協同的雙機制作用可有效解決代謝問題。全球多項臨床結果驗證HTD1801具有"一藥多效"的特性，能夠為患者帶來綜合獲益，包括改善胰島素敏感性、血糖控制、血脂降低、腎臟保護、體重減輕、肝臟獲益及抗炎等。基於此，HTD1801有潛力成為CKM領域的基礎性治療藥物。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 6月4日，Synology 群暉科技於 COMPUTEX 2026 盛大展出全新技術，現場更首度亮相創新的 AI 解決方案。本次參展涵蓋新一代 DiskStation Manager（DSM）作業系統、全新 ActiveProtect 備份專用一體機、完整的影像監控生態系、大幅升級的 Synology Office 套件，以及專為個人與家庭設計的 Bee Series 私有雲產品線。「資料是我們打造一切的核心，而信任則是穩固的基石。」Synology 董事長暨執行長翁英暉表示：「從企業基礎架構到個人雲端解決方案，我們研發的每款產品，都賦予使用者對資料的絕對主權。在毫不妥協的資安防護、可靠性與隱私保障之下，協助使用者充滿信心迎向未來的挑戰。」 更加智慧的 DSM 作業系統新一代 DSM 專為 AI 及企業需求而生，系統全面支援 GPU NAS 與 AI 硬體裝置，能落實全地端的 AI 推論與治理架構；而預計推出的 DSM Agent 則能橫跨系統，提供管理建議與設計自動化的工作流程。針對企業大規模部署需求，Cluster Manager 可整合多台系統至單一管理介面，並提供工作負載轉移、服務品質（QoS）控管與集中化保護機制；雲端監控平台 Active Insight 新增大規模部署功能，可快速部署多據點架構；最後全新升級的日誌中心，則能對接企業級可觀測性（Observability）平台，進一步強化資安防護與法規合規性。提升保護能力的 ActiveProtect Manager 2.0ActiveProtect Manager（APM） 2.0 擴大保護範圍，延伸至 AWS EC2、Azure VM、Proxmox、Nutanix AHV 與 Google Workspace，並支援跨平台還原，協助企業在混合雲與虛擬環境中保持資安韌性。本次還加入主動式威脅防禦，整合了 AI 驅動的異常與惡意程式偵測機制。同時，ActiveProtect 產品線迎來最新機種 DP5200 ，為企業帶來更高彈性的部署選擇。全新影像監控門禁控制、DVA 伺服器與混合雲監控Synology 影像監控生態系持續茁壯，首先展出門禁控制解決方案，包含 AC100 門禁控制器與 AR 系列讀卡機，並公開即將推出的 DC 系列半球型攝影機。再來智慧影像分析伺服器 DVA 系列導入了 AI 語意搜尋，與人員重識別（Re-identification）路徑追蹤等功能，有效提升監控效率。為使生態系更臻完善，Surveillance365 主打雲端監控服務（VSaaS），並能無縫整合地端的 Surveillance Station，為企業打造專屬的混合雲平台，完美實現遠端與多據點的安全監控。ChatPlus 與 Meet 強化溝通效率Synology Office Suite 正式增添生力軍 ChatPlus 與 Meet，為企業帶來具備細緻權限與管控功能的企業級通訊工具。兩款套件皆內建 AI 驅動的語音轉文字與翻譯功能，大幅提升團隊的協作效率，並確保所有資料完全落地、由企業 100% 掌控手中。專為個人與家庭打造的 Bee Series 私有雲生態系BeeStation與BeeStation Plus產品線，現在提供更豐富的容量與規格選擇，滿足多元的儲存需求。另外，使用者現在可透過BeeCamera功能，搭配Synology Cameras在BeeStation Plus上輕鬆展開監控；而基於macOS與Windows系統的 Synology Deep Search服務，則利用AI技術，提供高效的地端搜尋體驗，讓使用者在兼顧隱私的前提之下，精準找出個人裝置中的任何內容。欲了解更多Synology群暉科技產品和解決方案詳情或有任何需求， 歡迎至Synology群暉科技官網或聯繫 hk.event@synology.comMedia Contacts :Contact Us: https://www.synology.com/zh-hk/company/contact_us Synology Marketing & PR Specialist, Sandra Soh : sandrasoh@synology.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley  aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）宣布與北京天廣實生物技術股份有限公司（以下簡稱“天廣實”）達成商業化授權許可合作協議，獲得倍捷欣(R)（MIL62，通用名：奧妥珠單抗β注射液）在亞太地區（東南亞、印度、韓國、澳大利亞、新西蘭、中國香港、中國澳門及中國臺灣地區）的臨床開發及商業化權益。根據相關協議，雲頂新耀將向天廣實支付人民幣2,300萬元的首付款，以及最高不超過人民幣1.86億元的銷售里程碑款。天廣實可獲得該產品在亞太地區的銷售毛利額分成款項。此次合作將進一步強化雲頂新耀在腎科及自身免疫疾病等領域的亞太市場布局，並與現有腎科管線形成協同效應。雲頂新耀將依託已獲驗證的臨床開發及商業化能力，加速推動倍捷欣(R)的市場准入與商業化進程，持續釋放亞太區域的增長潛力，並推進公司在全球創新藥市場的長期戰略發展。倍捷欣(R)是天廣實自主研發的創新型第三代CD20抗體藥物。根據相關資料顯示，該藥物已於2026年2月在中國獲批上市，用於治療視神經脊髓炎譜系疾病（NMOSD），成為全球首款治療該疾病的CD20抗體，也是中國在該領域的首款國產藥物。倍捷欣(R)用於治療原發性膜性腎病（PMN）的新藥上市申請亦處於中國國家藥監局的「優先審評審批」階段，有望成為全球首款獲批的PMN特效藥物。此外，倍捷欣(R)正在進行的臨床III期試驗覆蓋系統性紅斑狼瘡（SLE）以及濾泡性淋巴瘤（FL）多個治療領域，並具備向其他自身免疫性疾病持續拓展的潛力。雲頂新耀董事會主席吳以芳表示：「我們非常高興能與天廣實就倍捷欣(R)達成此次合作。倍捷欣(R)不僅是全球首款獲批治療NMOSD的CD20抗體，也是一款具有差異化優勢和廣闊市場前景的創新藥，在腎科及自身免疫疾病領域展現出顯著的臨床潛力。此次合作將進一步豐富雲頂新耀在腎科及自身免疫領域的產品布局，並與現有管線形成良好的協同效應。依託公司已建立並持續強化的臨床開發及商業化能力，我們有信心加速推進倍捷欣(R)在亞太地區的開發與商業化進程，推動其儘快惠及更多患者，讓創新療法更快轉化為臨床可及性，並進一步提升公司在亞太及全球創新藥市場的影響力。」天廣實總裁陳魯寧表示：「我們非常欣喜與雲頂新耀達成倍捷欣(R)在亞太地區的合作。倍捷欣(R)作為全球首款獲批治療NMOSD的CD20靶向藥物，也是潛在全球首款治療PMN的特效藥物，擁有非常出色的產品競爭力與市場潛力。自產品上市以來，倍捷欣(R)在中國大陸地區已經取得了優異的商業化成績，此次合作將進一步強化倍捷欣(R)在整個亞太市場的商業化網路與品牌影響力，為中國大陸以外的更多腎科及自身免疫性疾病患者帶來「欣」希望。」倍捷欣(R)目前已在腎科及多個自身免疫疾病領域展現出顯著的臨床及治療價值，並具備廣闊的適應症拓展潛力。其在NMOSD、PMN及SLE等疾病領域的持續布局與進展，有望為患者帶來更多創新治療選擇。NMOSD是一種高復發率、高致殘率的中樞神經系統自身免疫性疾病，多發於青壯年女性。該病通常為急性或亞急性起病，可迅速進展，約90%的患者在三年內經歷復發，嚴重者可導致失明甚至癱瘓。倍捷欣(R)在單藥治療中顯示出降低復發風險的顯著優勢，並在療效數據中展現出優異表現，凸顯其作為單藥療法的臨床價值與治療便利性。PMN是成人腎病最常見的病理類型，約30%-40% 的患者在5-15年內可能進展為終末期腎病。目前全球範圍內尚無獲批的特效藥。臨床III期研究顯示，倍捷欣(R)單藥治療在臨床完全緩解、免疫學完全緩解及臨床緩解等各項指標上均展現出顯著優勢。此外，倍捷欣(R)具有良好的安全性和耐受性，並且給藥週期便捷，患者初始治療後，每六個月僅需進行一次靜脈注射，可顯著降低治療負擔，同時有助於提升長期依從性。SLE是一種慢性系統性自身免疫疾病，倍捷欣(R)目前處於臨床III期研究階段，具有24–28周的長給藥間隔優勢，可滿足患者對長效治療方案的臨床需求，有望為SLE患者提供更優治療選擇。此次合作被視為雲頂新耀提升腎科及自身免疫領域戰略縱深的重要舉措。隨著倍捷欣(R)在PMN等適應症上的開發與商業化推進，公司腎科產品矩陣將得到進一步補充，並強化現有管線的協同效應。此外，業內普遍認為，未來數年中國創新藥加速進入亞太市場將迎來重要發展機遇。憑藉臨床價值、可負擔性及可及性方面的綜合優勢，中國創新藥與亞太地區日益增長的醫療需求持續契合。雲頂新耀近年來持續推進亞太區域戰略布局，已逐步形成覆蓋臨床開發、市場准入及商業化運營的能力體系。通過引入倍捷欣(R)等具備差異化臨床價值的創新產品，雲頂新耀正進一步拓展區域產品組合及市場覆蓋，推動公司腎科及自身免疫領域商業化價值的釋放，並為亞太業務發展注入新的增長動能。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 今年，高瓴資本以每股5.8港元、溢價12%的代價一舉拿下現代牙科1.61億股，躍升為第二大股東。市場一度好奇：這究竟是財務投資，還是對全球義齒龍頭價值的重倉押注？帶著這個疑問，我們走進了現代牙科位於東莞松山湖的全球核心生產基地，試圖從產業邏輯出發，梳理2026年公司必須關注的幾大核心亮點。（現代牙科東莞基地調研相關影像資料）數碼化滲透加速，行業拉開結構性重塑大幕全球義齒行業正處於從"手工作坊"向"數碼化智造"轉型的關鍵拐點。當前口內掃描器在牙醫端的普及率僅15%-25%，仍屬早期滲透階段。隨著設備降價和教學體系更新，未來幾年將進入加速普及期。數碼化帶來的變化是顛覆性的：-交付週期從傳統9-11天壓縮到7天以內；-返工率從行業平均6%-8%銳減至1%-2%；-數碼化能力正成為牙醫選擇供應商的首要決策變數。據美國牙科技工所協會數據，美國牙科實驗室65%的銷售來自單人執業的牙醫診所，這些機構普遍缺乏對數碼化轉型的認知。而現代牙科作為全球義齒行業數碼化先鋒，正成為這廣闊市場的革新者，加速市場教育的同時也在不斷提升自身佔有率。行業數碼化轉型大勢所趨，現代牙科將充分受益行業轉型紅利。集中生產+自有分銷，鑄就全球化雙輪驅動壁壘現代牙科的核心競爭模式可概括為"低成本國家集中生產、高附加值市場全球分銷"。公司在東莞、越南、泰國等地建立了多個集中化生產基地，不僅有效分散地緣政治風險，也為未來3-5年儲備了充裕的產能擴張空間。東莞基地2024年完成深圳產能整合，運營效率顯著提升；越南工廠進入成熟期；泰國Hexa Ceram市占率超28%，成為輻射東南亞的重要支點。更關鍵的是，公司通過近十年的並購整合，搭建起覆蓋全球的自有獨家分銷網路。旗下Elysee、Labocast、洋紫荊等本地化品牌，配合集中生產模式，帶來了更高的定價權與客戶粘性，這是許多代工廠難以逾越的護城河。從代工到方案設計，數碼化升維賦能牙醫現代牙科已悄然完成角色躍遷——從被動接單的加工廠，轉型為主動為牙醫賦能的"數碼化解決方案提供商"。通過整合口內掃描、面部掃描、CBCT等多源醫療數據，公司能直接為牙醫輸出治療方案設計、笑容模擬、治療前後對比，從而將自身價值從"產品供應"升級為"診所營收增長的催化劑"。這一能力顯著提升了高單價療程（如種植、貼面、矯正）的轉化率，並深化了牙醫對公司的依賴。同時，基於40年複雜案例資料庫推進的"混合療程+交叉銷售"戰略，將義齒修復與旗下自研透明矯治器TrioClear、牙齒美容貼面等打包為整體笑容設計服務。2025年，TrioClear已實現收益5,970萬港元，兩年複合增長率達33.2%，驗證了品牌力和管道協同效應。門檻抬高、長尾出清，全球複製能力加速收割數碼化義齒製造對資本、設備、軟體、數據處理和技師培訓提出了極高要求，涵蓋口內掃描檔案處理、CAD/CAM、3D打印、三維成像等數碼化技術，實現從數據採集、診斷設計到協助醫生治療實施的全流程數碼化。這正在系統性地擠走缺乏資金和技術的小型技工所，釋放出大量市場份額。現代牙科憑藉規模效應和資金優勢，正被動兼主動收割這些份額。與此同時，公司覆蓋全球的銷售網絡和牙科智庫生態，賦予了其罕見的"從1到100"的複製能力。任何在單一市場驗證成功的創新方案（如TrioClear），均可通過自有管道迅速導入歐美、澳洲、大中華等其他市場。這種全球推廣效率，是區域性廠商根本難以望其項背的。強化醫療數據處理能力，成為AI時代的口腔數據巨頭公司每年處理近300萬宗修復案例，積累的是一份海量、多源、高標注品質的口腔醫療數據資產。在AI大模型重塑各行各業的當下，這一數據金礦的價值愈發凸顯。智能演算法已可輔助牙齒形態設計、自動檢測缺陷，進一步提升效率和一致性；未來，基於真實世界數據的持續學習，更有望不斷孵化出新的治療方案與產品。高瓴入局，強強聯手打開戰略協同新空間高瓴資本的9.35億港元入場絕非簡單的財務投注。其在醫療健康領域的深厚根基，尤其是對時代天使等牙科標杆項目的成功運作，為現代牙科注入了豐富的想像空間：資本上增強並購整合與研發實力；資源上對接頂級的投後管理與行業專家網路；技術上高瓴在AI及大數據領域的投資積累，有望與現代牙科的口腔數據資產形成戰略協同，助攻智能化轉型。這更像是高瓴對"全球牙科數碼化基礎設施"投下的一張長期信任票。2026年的現代牙科，正處在從"義齒代工廠"向"全球牙科數碼化服務平臺"躍遷的關鍵節點。其價值內核已不單是產能規模，更體現在全球自有分銷網路、集中生產與本土品牌協同、數碼化主動設計、海量數據資產、外部戰略協同這五大支柱之上。在行業數碼化加速、小型競爭者出清、全球牙科剛需穩步增長的大背景下，公司有望持續實現收入的高單位數至雙位數增長，並帶動毛利率中樞穩步抬升。來源：港股投研所 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）宣布與Travere Therapeutics, Inc.（NASDAQ: TVTX，以下簡稱「Travere Therapeutics」）達成獨家授權許可與合作協議。根據協議，Travere Therapeutics將獲得EVER001（希布替尼，civorebrutinib）除大中華區及部分東南亞國家以外區域的獨家開發及商業化權益。此次合作將加EVER001的全球臨床開發與商業化進程，為全球腎病患者帶來創新治療選擇。根據協議，雲頂新耀將獲得1.125億美元的首付款，以及在最多五個適應症上獲得高達10.3億美元的開發、註冊及商業化里程碑付款。此外，基於EVER001的未來年度淨銷售額，雲頂新耀將獲得從高個位數至雙位數百分比的分級特許權使用費。該交易將在滿足特定交割條件及完成必要監管程式後完成交割。本次雲頂新耀的合作方Travere Therapeutics是一家在納斯達克上市（股票代碼：TVTX）的美國生物制藥公司，重點布局罕見腎小球疾病領域，尤其聚焦IgA腎病和局灶節段性腎小球硬化（FSGS），並在研用於同型半胱氨酸尿症（HCU）等罕見遺傳代謝疾病的治療專案。其核心產品FILSPARI®（sparsentan）是一種口服雙重內皮素受體拮抗劑及血管緊張素II AT1受體拮抗劑，已獲美國FDA批准用於治療IgA腎病及FSGS，成為全球首個且唯一獲批用於FSGS治療的藥物，進一步強化其在腎病治療領域的領先地位。EVER001是一款新一代共價可逆布魯頓酪氨酸激酶（BTK）抑制劑，具備「一個可以開發多種適應症的藥物（pipeline-in-a-product）」的開發潛力。與共價不可逆BTK抑制劑相比，EVER001作為一款潛在的同類最佳產品，在保持高活性的同時具有高選擇性，避免持續抑制帶來的毒副作用。近年來，雲頂新耀憑藉強大的臨床開發能力，在全球多中心臨床試驗推進、自主研發管線臨床驗證及國際授權合作等方面取得了多項里程碑進展。在EVER001的臨床開發中，雲頂新耀此前公布用於治療中國原發性膜性腎病（PMN）患者的1b/2a期臨床研究數據顯示，EVER001展現出快速、深度且持久的免疫學和臨床緩解，停藥後仍持續獲益，安全性高，耐受性強。這些結果支持EVER001具有治療以蛋白尿為特徵的自身免疫性腎小球疾病的潛力。EVER001具備在多種免疫介導性腎小球疾病中的開發潛力，包括PMN、IgA腎病、微小病變性腎病（MCD）、FSGS及狼瘡性腎炎等。這類疾病均與異常免疫反應引發的腎小球損傷相關，可導致蛋白尿和腎功能下降，嚴重時甚至可能發展至終末期腎病，需要透析或腎移植治療。EVER001有望為全球逾1000萬名相關患者提供新的治療選擇。據悉，Travere Therapeutics計畫在PMN、免疫介導的FSGS及MCD等適應症中推進EVER001的臨床開發，並有望進一步拓展至更多適應症領域。雲頂新耀董事會主席吳以芳表示：「我們非常高興與Travere Therapeutics達成此次合作。這一合作將加速EVER001的全球開發與商業化進程，進一步釋放其在自身免疫性腎臟疾病領域的臨床潛力與商業價值，為全球患者帶來更多創新治療選擇。作為公司自主研發的潛在同類最佳創新藥物，EVER001已在原發性膜性腎病等自身免疫性腎臟疾病治療中展現出積極潛力。憑藉其差異化作用機制，EVER001具備拓展至多種自身免疫性腎臟疾病的潛力，持續釋放其臨床開發潛力。公司始終堅持『BD合作+自主研發』雙輪驅動戰略，持續推進戰略性業務拓展與自主研發，不斷完善全球研發體系建設，持續提升在全球創新藥領域的綜合競爭力。Travere Therapeutics在美國已有獲批的腎科產品，在腎病藥物開發、註冊及商業化方面積累了豐富經驗與成熟能力。雙方將充分發揮各自優勢，共同推進EVER001在原發性膜性腎病、免疫介導的局灶節段性腎小球硬化及微小病變性腎病上的全球臨床開發，為全球患者帶來更多突破性治療選擇。」Travere Therapeutics總裁兼首席執行官Eric Dube博士表示：「EVER001作為我們罕見腎病領域管線的重要戰略性補充，具有高度協同價值，並有望成為覆蓋多種免疫介導罕見腎病的同類最佳療法。罕見腎病患者目前仍面臨巨大的未滿足臨床需求。我們認為，在IgA腎病和FSGS領域已取得的階段性進展，僅是這一治療領域潛力釋放的開始。Travere Therapeutics持續推動該領域的重要創新與突破，憑藉在罕見腎病領域積累的深厚專業經驗、成熟的研發與商業化能力，以及對患者的持續承諾，我們將不斷推動創新，為患者帶來更多突破性治療選擇。作為一款具有差異化優勢的口服可逆BTK抑制劑，EVER001在原發性膜性腎病中已展現出令人鼓舞的概念驗證數據，其作用機制可覆蓋免疫介導的局灶節段性腎小球硬化、微小病變腎病等更多疾病領域。我們相信，EVER001將為罕見腎病患者帶來更具重要意義的治療突破，進一步推動該領域治療格局的重塑。」此次雲頂新耀與Travere Therapeutics的合作，進一步推動了EVER001的全球化進程，也是雲頂新耀創新藥價值進一步釋放的體現。目前，雲頂新耀已形成由耐賦康®、MT1013及EVER001組成的腎科產品矩陣，覆蓋IgA腎病、繼發性甲狀旁腺功能亢進症（SHPT）及多種免疫介導性腎臟疾病。通過持續深化腎科領域戰略布局，雲頂新耀正加速全球布局，以創新療法為更多患者提供可及、可靠的治療方案。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com